CLAS Trial: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==CLAS Trial== ===Objective=== To determine whether combined therapy with the lipid lowering agents colestipol hydrochl..." |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Objective== | |||
To determine whether combined therapy with the [[lipid]] lowering agents [[colestipol]] hydrochloride (30g daily) plus niacin (3-12g daily) would produce significant change in coronary, carotid, and femoral artery [[atherosclerosis]] and coronary bypass [[graft]] lesions as determined by [[angiography]]. Also, to determine possible correlations between lesion changes and plasma lipid and [[lipoprotein]] [[cholesterol]] levels and to explore interrelationships of atherosclerosis change in femoral, coronary, and [[carotid arteries]]. | To determine whether combined therapy with the [[lipid]] lowering agents [[colestipol]] hydrochloride (30g daily) plus niacin (3-12g daily) would produce significant change in coronary, carotid, and femoral artery [[atherosclerosis]] and coronary bypass [[graft]] lesions as determined by [[angiography]]. Also, to determine possible correlations between lesion changes and plasma lipid and [[lipoprotein]] [[cholesterol]] levels and to explore interrelationships of atherosclerosis change in femoral, coronary, and [[carotid arteries]]. | ||
==Methods== | |||
CLAS (Cholesterol Lowering Atherosclerosis Study) was a randomized, selectively blinded study wherein 188 men, with known previous [[coronary artery bypass graft]]s, were randomized to diet plus placebo or diet plus combined lipid lowering therapy consisting of colestipol and [[niacin]] and followed up at 2 years and 4 years. | CLAS (Cholesterol Lowering Atherosclerosis Study) was a randomized, selectively blinded study wherein 188 men, with known previous [[coronary artery bypass graft]]s, were randomized to diet plus placebo or diet plus combined lipid lowering therapy consisting of colestipol and [[niacin]] and followed up at 2 years and 4 years. | ||
==Results== | |||
The following results were noted:<ref name="pmid3295315">{{cite journal |author=Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L |title=Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts |journal=JAMA |volume=257 |issue=23 |pages=3233–40 |year=1987 |month=June |pmid=3295315 |doi= |url=}}</ref> | The following results were noted:<ref name="pmid3295315">{{cite journal |author=Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L |title=Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts |journal=JAMA |volume=257 |issue=23 |pages=3233–40 |year=1987 |month=June |pmid=3295315 |doi= |url=}}</ref> | ||
* Treatment group had a 37% raise in HDL-C levels and a 43% reduction in LDL-C levels. | * Treatment group had a 37% raise in HDL-C levels and a 43% reduction in LDL-C levels. | ||
| Line 18: | Line 17: | ||
* Atherosclerosis regression occurred in 16.2% of colestipol-niacin treated vs 2.4% placebo treated | * Atherosclerosis regression occurred in 16.2% of colestipol-niacin treated vs 2.4% placebo treated | ||
==Conclusion== | |||
The benefit of combined nicotinic acid and colestipol therapy was most prominent in patients with baseline plasma cholesterol levels above 240 mg/dL.<ref name="pmid2243429">{{cite journal |author=Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH |title=Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up |journal=JAMA |volume=264 |issue=23 |pages=3013–7 |year=1990 |month=December |pmid=2243429 |doi= |url=}}</ref><ref name="pmid8616937">{{cite journal |author=Azen SP, Mack WJ, Cashin-Hemphill L, ''et al.'' |title=Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study |journal=Circulation |volume=93 |issue=1 |pages=34–41 |year=1996 |month=January |pmid=8616937 |doi= |url=}}</ref><ref name="pmid3327654">{{cite journal |author=Blankenhorn DH, Johnson RL, Nessim SA, Azen SP, Sanmarco ME, Selzer RH |title=The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results |journal=Control Clin Trials |volume=8 |issue=4 |pages=356–87 |year=1987 |month=December |pmid=3327654 |doi= |url=}}</ref><ref name="pmid1991366">{{cite journal |author=Blankenhorn DH, Azen SP, Crawford DW, ''et al.'' |title=Effects of colestipol-niacin therapy on human femoral atherosclerosis |journal=Circulation |volume=83 |issue=2 |pages=438–47 |year=1991 |month=February |pmid=1991366 |doi= |url=}}</ref> | The benefit of combined nicotinic acid and colestipol therapy was most prominent in patients with baseline plasma cholesterol levels above 240 mg/dL.<ref name="pmid2243429">{{cite journal |author=Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH |title=Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up |journal=JAMA |volume=264 |issue=23 |pages=3013–7 |year=1990 |month=December |pmid=2243429 |doi= |url=}}</ref><ref name="pmid8616937">{{cite journal |author=Azen SP, Mack WJ, Cashin-Hemphill L, ''et al.'' |title=Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study |journal=Circulation |volume=93 |issue=1 |pages=34–41 |year=1996 |month=January |pmid=8616937 |doi= |url=}}</ref><ref name="pmid3327654">{{cite journal |author=Blankenhorn DH, Johnson RL, Nessim SA, Azen SP, Sanmarco ME, Selzer RH |title=The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results |journal=Control Clin Trials |volume=8 |issue=4 |pages=356–87 |year=1987 |month=December |pmid=3327654 |doi= |url=}}</ref><ref name="pmid1991366">{{cite journal |author=Blankenhorn DH, Azen SP, Crawford DW, ''et al.'' |title=Effects of colestipol-niacin therapy on human femoral atherosclerosis |journal=Circulation |volume=83 |issue=2 |pages=438–47 |year=1991 |month=February |pmid=1991366 |doi= |url=}}</ref> | ||
| Line 27: | Line 26: | ||
[[Category:Lipopedia]] | [[Category:Lipopedia]] | ||
[[Category:HDL]] | [[Category:HDL]] | ||
[[Category:Clinical trials]] | |||
Revision as of 23:19, 17 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
CLAS Trial On the Web |
|
American Roentgen Ray Society Images of CLAS Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
To determine whether combined therapy with the lipid lowering agents colestipol hydrochloride (30g daily) plus niacin (3-12g daily) would produce significant change in coronary, carotid, and femoral artery atherosclerosis and coronary bypass graft lesions as determined by angiography. Also, to determine possible correlations between lesion changes and plasma lipid and lipoprotein cholesterol levels and to explore interrelationships of atherosclerosis change in femoral, coronary, and carotid arteries.
Methods
CLAS (Cholesterol Lowering Atherosclerosis Study) was a randomized, selectively blinded study wherein 188 men, with known previous coronary artery bypass grafts, were randomized to diet plus placebo or diet plus combined lipid lowering therapy consisting of colestipol and niacin and followed up at 2 years and 4 years.
Results
The following results were noted:[1]
- Treatment group had a 37% raise in HDL-C levels and a 43% reduction in LDL-C levels.
- Regression of atherosclerosis, as measured by angiography, was greater with combined drug treatment at 2 years and at 4 years.
- Reduction in the percentage of subjects with new atheroma formation in native coronary arteries.
- Significantly reduced percentage of subjects with new lesions or any adverse change in bypass grafts.
- Atherosclerosis regression occurred in 16.2% of colestipol-niacin treated vs 2.4% placebo treated
Conclusion
The benefit of combined nicotinic acid and colestipol therapy was most prominent in patients with baseline plasma cholesterol levels above 240 mg/dL.[2][3][4][5]
References
- ↑ Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L (1987). "Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts". JAMA. 257 (23): 3233–40. PMID 3295315. Unknown parameter
|month=ignored (help) - ↑ Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH (1990). "Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up". JAMA. 264 (23): 3013–7. PMID 2243429. Unknown parameter
|month=ignored (help) - ↑ Azen SP, Mack WJ, Cashin-Hemphill L; et al. (1996). "Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study". Circulation. 93 (1): 34–41. PMID 8616937. Unknown parameter
|month=ignored (help) - ↑ Blankenhorn DH, Johnson RL, Nessim SA, Azen SP, Sanmarco ME, Selzer RH (1987). "The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results". Control Clin Trials. 8 (4): 356–87. PMID 3327654. Unknown parameter
|month=ignored (help) - ↑ Blankenhorn DH, Azen SP, Crawford DW; et al. (1991). "Effects of colestipol-niacin therapy on human femoral atherosclerosis". Circulation. 83 (2): 438–47. PMID 1991366. Unknown parameter
|month=ignored (help)